ANTCARD

Analogues Of Thromboxane For The Treatment Of Cardiovascular Disease

 Coordinatore UNIVERSITY OF BRISTOL 

 Organization address address: TYNDALL AVENUE SENATE HOUSE
city: BRISTOL
postcode: BS8 1TH

contact info
Titolo: Mrs.
Nome: Maria
Cognome: Davies
Email: send email
Telefono: +44 117 3317352

 Nazionalità Coordinatore United Kingdom [UK]
 Totale costo 221˙606 €
 EC contributo 221˙606 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2013-IEF
 Funding Scheme MC-IEF
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-03-01   -   2016-02-29

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITY OF BRISTOL

 Organization address address: TYNDALL AVENUE SENATE HOUSE
city: BRISTOL
postcode: BS8 1TH

contact info
Titolo: Mrs.
Nome: Maria
Cognome: Davies
Email: send email
Telefono: +44 117 3317352

UK (BRISTOL) coordinator 221˙606.40

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

disease    thromboxane    aspirin    cardiovascular    acids    alternative    platelets    synthesis    fatty    thromboxanes    interfere    biosynthesis    block    pharmacology    antibodies    platelet   

 Obiettivo del progetto (Objective)

'Cardiovascular disease is the leading cause of death in the developed world; in Europe it led to over 4 million deaths (47%) last year. Platelets play an essential role in haemostasis and a critical role in thrombosis and cardiovascular disease. Their activation by thromboxane is crucial for thrombus formation but this can lead to myocardial infarction or stroke. Due to the important role of platelets in cardiovascular disease, patients at risk of thrombotic events are routinely prescribed anti-platelet drugs that interfere with the amplification of platelet function (e.g. aspirin). The mechanism of action of aspirin is to block the biosynthesis of thromboxane, a fatty acid that activates platelet formation and aggregation. However, it has side effects. Alternative COX inhibitors that block production of related fatty acids have been developed, but have had to be withdrawn from the market due to side effects. An alternative strategy that does not interfere with the biosynthesis of thromboxanes is described. During the biosynthesis of thromboxanes other fatty acids e.g. prostaglandins are also produced and their elimination causes side effects. Instead, we plan to allow the body to make thromboxane, but to develop an antibody to remove it from the system, so that it does not have a chance to cause harmful effects. However, antibodies cannot be generated of thromboxane itself as it is too unstable (half life 35 s). Hence, an analogue that mimics thromboxane in having a highly strained acetal motif will be synthesized, stabilized by incorporating fluorine substituents at strategic positions. Initially the methodology will be developed by completing a short synthesis of the hydrolysed form of thromboxane and then go on to make the fluorinated version. A commercial enterprise will raise antibodies to this molecule and it will be tested for activity in the pharmacology department in the university. The project brings together leading groups in synthesis and pharmacology.'

Altri progetti dello stesso programma (FP7-PEOPLE)

BRAINPROTECT (2014)

Presenilin 2 - a protector against Alzheimer's disease

Read More  

ERIS (2010)

Experimental Resource for the Investigation of dialogue procesSes

Read More  

MEDIAGIST (2014)

Summarisation and Sentiment Analysis for Evolving Multilingual Media Content

Read More